奇托桑纳米颗粒用于胃食道逆流性疾病治疗
1Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia.
Polymers
|August 26, 2023
概括
素纳米颗粒为胃食道逆流性疾病 (GERD) 治疗提供了一个有前途的纳米技术方法. 这些纳米颗粒可以实现向药物输送和受控释放,从而有可能改善GERD管理.
科学领域:
- 纳米技术 纳米技术
- 胃肠病学 胃肠病学
- 生物材料是一种生物材料.
背景情况:
- 胃食道逆流性疾病 (GERD) 是一种慢性疾病,由胃酸逆流进入食道引起.
- 目前的GERD治疗可能存在局限性,需要新的治疗策略.
研究的目的:
- 审查纳米技术的潜力,特别是素纳米颗粒 (CSNPs),作为一种新的治疗GERD.
- 探索基于CSNP的输送系统对食道疾病的优势和挑战.
主要方法:
- 审查关于奇托桑纳米颗粒及其在药物输送中的应用现有的文献.
- 分析不同的纳米粒子配方 (凝,微球,涂层) 用于食道药物输送.
- 调查CSNP针对涉及GERD病变发生的分子途径的潜力.
主要成果:
- 素纳米颗粒 (CSNPs) 具有生物相容性,生物降解性和受控药物释放性.
- 目前正在开发各种CSNP输送系统,以增强药物保留和食道中的向.
- 可以设计CSNP来调节酸调节,保护食道组织,减少炎症.
结论:
- 基托桑纳米颗粒为开发创新的GERD治疗提供了重大机会.
- 需要解决配方稳定性,可扩展性和监管批准方面的挑战.
- 未来的研究可能将重点放在将CSNP与现有疗法 (如质子抑制剂) 结合起来,以获得协同效应.
更多相关视频
相关概念视频
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
551
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
551
Gastroesophageal Reflux Disease II: Clinical Features and Management
111
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
111
Peptic Ulcer Disease IV: Management
110
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
110
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
493
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
493
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
303
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
303
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
198
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
198


